Premium
Brain insulin, insulin‐like growth factor 1 and glucagon‐like peptide 1 signalling in Alzheimer’s disease
Author(s) -
Ferreira Sergio T.
Publication year - 2021
Publication title -
journal of neuroendocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.062
H-Index - 116
eISSN - 1365-2826
pISSN - 0953-8194
DOI - 10.1111/jne.12959
Subject(s) - insulin , insulin resistance , signalling , endocrinology , medicine , diabetes mellitus , insulin receptor , neuroscience , cognitive decline , disease , glucagon , alzheimer's disease , psychology , biology , dementia , microbiology and biotechnology
Although the brain was once considered an insulin‐independent organ, insulin signalling is now recognised as being central to neuronal health and to the function of synapses and brain circuits. Defective brain insulin signalling, as well as related signalling by insulin‐like growth factor 1 (IGF‐1), is associated with neurological disorders, including Alzheimer's disease, suggesting that cognitive impairment could be related to a state of brain insulin resistance. Here, I briefly review key epidemiological/clinical evidence of the association between diabetes, cognitive decline and AD, as well as findings of reduced components of insulin signalling in AD brains, which led to the initial suggestion that AD could be a type of brain diabetes. Particular attention is given to recent studies illuminating mechanisms leading to neuronal insulin resistance as a key driver of cognitive impairment in AD. Evidence of impaired IGF‐1 signalling in AD is also examined. Finally, we discuss potentials and possible limitations of recent and on‐going therapeutic approaches based on our increased understanding of the roles of brain signalling by insulin, IGF‐1 and glucagon‐like peptide 1 in AD.